Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 354 entries
Sorted by: Best Match Show Resources per page
cis-Decalin oxidation as a stereochemical probe of in-MOF versus on-MOF catalysis.

Chemical communications (Cambridge, England)

Cardenal AD, Jeong Park H, Chalker CJ, Ortiz KG, Powers DC.
PMID: 28612073
Chem Commun (Camb). 2017 Jun 29;53(53):7377-7380. doi: 10.1039/c7cc02570j.

Development of catalyst-controlled C-H hydroxylation could provide direct access to valuable synthetic targets, such as primary metabolites. Here, we report a new family of porous materials, comprised of 2-dimensional metalloporphyrin layers and flexible aliphatic linkers, and demonstrate C-H hydroxylation...

Cite
Cardenal AD, Jeong Park H, Chalker CJ, et al. cis-Decalin oxidation as a stereochemical probe of in-MOF versus on-MOF catalysis. Chem Commun (Camb). 2017;53(53):7377-7380doi: 10.1039/c7cc02570j.
Cardenal, A. D., Jeong Park, H., Chalker, C. J., Ortiz, K. G., & Powers, D. C. (2017). cis-Decalin oxidation as a stereochemical probe of in-MOF versus on-MOF catalysis. Chemical communications (Cambridge, England), 53(53), 7377-7380. https://doi.org/10.1039/c7cc02570j
Cardenal, Ashley D, et al. "cis-Decalin oxidation as a stereochemical probe of in-MOF versus on-MOF catalysis." Chemical communications (Cambridge, England) vol. 53,53 (2017): 7377-7380. doi: https://doi.org/10.1039/c7cc02570j
Cardenal AD, Jeong Park H, Chalker CJ, Ortiz KG, Powers DC. cis-Decalin oxidation as a stereochemical probe of in-MOF versus on-MOF catalysis. Chem Commun (Camb). 2017 Jun 29;53(53):7377-7380. doi: 10.1039/c7cc02570j. PMID: 28612073.
Copy Download .nbib Format: NLM
The Diagnosis and Manifestations of Liver Injury Secondary to Off-Label Androgenic Anabolic Steroid Use.

Case reports in gastroenterology

Cabb E, Baltar S, Powers DW, Mohan K, Martinez A, Pitts E.
PMID: 27721739
Case Rep Gastroenterol. 2016 Sep 12;10(2):499-505. doi: 10.1159/000448883. eCollection 2016.

Drug-induced liver injury (DILI) presents as a broad spectrum of adverse drug reactions which can range from a mild elevation in liver enzymes to fulminant liver failure. The primary goal is to identify DILI early when the patient's liver...

Cite
Cabb E, Baltar S, Powers DW, et al. The Diagnosis and Manifestations of Liver Injury Secondary to Off-Label Androgenic Anabolic Steroid Use. Case Rep Gastroenterol. 2016;10(2):499-505doi: 10.1159/000448883.
Cabb, E., Baltar, S., Powers, D. W., Mohan, K., Martinez, A., & Pitts, E. (2016). The Diagnosis and Manifestations of Liver Injury Secondary to Off-Label Androgenic Anabolic Steroid Use. Case reports in gastroenterology, 10(2), 499-505. https://doi.org/10.1159/000448883
Cabb, Elena, et al. "The Diagnosis and Manifestations of Liver Injury Secondary to Off-Label Androgenic Anabolic Steroid Use." Case reports in gastroenterology vol. 10,2 (2016): 499-505. doi: https://doi.org/10.1159/000448883
Cabb E, Baltar S, Powers DW, Mohan K, Martinez A, Pitts E. The Diagnosis and Manifestations of Liver Injury Secondary to Off-Label Androgenic Anabolic Steroid Use. Case Rep Gastroenterol. 2016 Sep 12;10(2):499-505. doi: 10.1159/000448883. eCollection 2016. PMID: 27721739; PMCID: PMC5043289.
Copy Download .nbib Format: NLM
Hematologic complications, healthcare utilization, and costs in commercially insured patients with myelodysplastic syndrome receiving supportive care.

American health & drug benefits

Powers A, Faria C, Broder MS, Chang E, Cherepanov D.
PMID: 24991341
Am Health Drug Benefits. 2012 Nov;5(7):455-65.

BACKGROUND: Myelodysplastic syndrome (MDS) is rare in people aged

Cite
Powers A, Faria C, Broder MS, et al. Hematologic complications, healthcare utilization, and costs in commercially insured patients with myelodysplastic syndrome receiving supportive care. Am Health Drug Benefits. 2012;5(7):455-65
Powers, A., Faria, C., Broder, M. S., Chang, E., & Cherepanov, D. (2012). Hematologic complications, healthcare utilization, and costs in commercially insured patients with myelodysplastic syndrome receiving supportive care. American health & drug benefits, 5(7), 455-65.
Powers, Annette, et al. "Hematologic complications, healthcare utilization, and costs in commercially insured patients with myelodysplastic syndrome receiving supportive care." American health & drug benefits vol. 5,7 (2012): 455-65.
Powers A, Faria C, Broder MS, Chang E, Cherepanov D. Hematologic complications, healthcare utilization, and costs in commercially insured patients with myelodysplastic syndrome receiving supportive care. Am Health Drug Benefits. 2012 Nov;5(7):455-65. PMID: 24991341; PMCID: PMC4031699.
Copy Download .nbib Format: NLM
Heat dissipation during hovering and forward flight in hummingbirds.

Royal Society open science

Powers DR, Tobalske BW, Wilson JK, Woods HA, Corder KR.
PMID: 27019742
R Soc Open Sci. 2015 Dec 16;2(12):150598. doi: 10.1098/rsos.150598. eCollection 2015 Dec.

Flying animals generate large amounts of heat, which must be dissipated to avoid overheating. In birds, heat dissipation is complicated by feathers, which cover most body surfaces and retard heat loss. To understand how birds manage heat budgets during...

Cite
Powers DR, Tobalske BW, Wilson JK, et al. Heat dissipation during hovering and forward flight in hummingbirds. R Soc Open Sci. 2015;2(12):150598doi: 10.1098/rsos.150598.
Powers, D. R., Tobalske, B. W., Wilson, J. K., Woods, H. A., & Corder, K. R. (2015). Heat dissipation during hovering and forward flight in hummingbirds. Royal Society open science, 2(12), 150598. https://doi.org/10.1098/rsos.150598
Powers, Donald R, et al. "Heat dissipation during hovering and forward flight in hummingbirds." Royal Society open science vol. 2,12 (2015): 150598. doi: https://doi.org/10.1098/rsos.150598
Powers DR, Tobalske BW, Wilson JK, Woods HA, Corder KR. Heat dissipation during hovering and forward flight in hummingbirds. R Soc Open Sci. 2015 Dec 16;2(12):150598. doi: 10.1098/rsos.150598. eCollection 2015 Dec. PMID: 27019742; PMCID: PMC4807464.
Copy Download .nbib Format: NLM
If DSME Were a Pill, Would You Prescribe It?.

Diabetes spectrum : a publication of the American Diabetes Association

Powers MA.
PMID: 28270715
Diabetes Spectr. 2017 Feb;30(1):51-57. doi: 10.2337/ds16-0078.

No abstract available.

Cite
Powers MA. If DSME Were a Pill, Would You Prescribe It?. Diabetes Spectr. 2017;30(1):51-57doi: 10.2337/ds16-0078.
Powers, M. A. (2017). If DSME Were a Pill, Would You Prescribe It?. Diabetes spectrum : a publication of the American Diabetes Association, 30(1), 51-57. https://doi.org/10.2337/ds16-0078
Powers, Margaret A. "If DSME Were a Pill, Would You Prescribe It?." Diabetes spectrum : a publication of the American Diabetes Association vol. 30,1 (2017): 51-57. doi: https://doi.org/10.2337/ds16-0078
Powers MA. If DSME Were a Pill, Would You Prescribe It?. Diabetes Spectr. 2017 Feb;30(1):51-57. doi: 10.2337/ds16-0078. PMID: 28270715; PMCID: PMC5309907.
Copy Download .nbib Format: NLM
Response to Comment on Powers et al. Diabetes Self-management Education and Support in Type 2 Diabetes: A Joint Position Statement of the American Diabetes Association, the American Association of Diabetes Educators, and the Academy of Nutrition and Dietetics. Diabetes Care 2015;38:1372-1382.

Diabetes care

Powers MA, Marrero DG.
PMID: 26696664
Diabetes Care. 2016 Jan;39(1):e17. doi: 10.2337/dci15-0009.

No abstract available.

Cite
Powers MA, Marrero DG. Response to Comment on Powers et al. Diabetes Self-management Education and Support in Type 2 Diabetes: A Joint Position Statement of the American Diabetes Association, the American Association of Diabetes Educators, and the Academy of Nutrition and Dietetics. Diabetes Care 2015;38:1372-1382. Diabetes Care. 2016;39(1):e17doi: 10.2337/dci15-0009.
Powers, M. A., & Marrero, D. G. (2016). Response to Comment on Powers et al. Diabetes Self-management Education and Support in Type 2 Diabetes: A Joint Position Statement of the American Diabetes Association, the American Association of Diabetes Educators, and the Academy of Nutrition and Dietetics. Diabetes Care 2015;38:1372-1382. Diabetes care, 39(1), e17. https://doi.org/10.2337/dci15-0009
Powers, Margaret A, and Marrero, David G. "Response to Comment on Powers et al. Diabetes Self-management Education and Support in Type 2 Diabetes: A Joint Position Statement of the American Diabetes Association, the American Association of Diabetes Educators, and the Academy of Nutrition and Dietetics. Diabetes Care 2015;38:1372-1382." Diabetes care vol. 39,1 (2016): e17. doi: https://doi.org/10.2337/dci15-0009
Powers MA, Marrero DG. Response to Comment on Powers et al. Diabetes Self-management Education and Support in Type 2 Diabetes: A Joint Position Statement of the American Diabetes Association, the American Association of Diabetes Educators, and the Academy of Nutrition and Dietetics. Diabetes Care 2015;38:1372-1382. Diabetes Care. 2016 Jan;39(1):e17. doi: 10.2337/dci15-0009. PMID: 26696664.
Copy Download .nbib Format: NLM
Isolation and Characterization of an Actin Promoter from the Red Abalone (Haliotis rufescens).

Marine biotechnology (New York, N.Y.)

Gómez-Chiarri M, Kirby VL, Powers DA.
PMID: 10384001
Mar Biotechnol (NY). 1999 May;1(3):269-278. doi: 10.1007/pl00011776.

: We have isolated and characterized the 5'-flanking and part of the coding region of an actin gene from the red abalone Haliotis rufescens. There is high sequence homology between the abalone actin coding region and actins from other...

Cite
Gómez-Chiarri M, Kirby VL, Powers DA. Isolation and Characterization of an Actin Promoter from the Red Abalone (Haliotis rufescens). Mar Biotechnol (NY). 1999;1(3):269-278doi: 10.1007/pl00011776.
Gómez-Chiarri, M., Kirby, V. L., & Powers, D. A. (1999). Isolation and Characterization of an Actin Promoter from the Red Abalone (Haliotis rufescens). Marine biotechnology (New York, N.Y.), 1(3), 269-278. https://doi.org/10.1007/pl00011776
Gómez-Chiarri, et al. "Isolation and Characterization of an Actin Promoter from the Red Abalone (Haliotis rufescens)." Marine biotechnology (New York, N.Y.) vol. 1,3 (1999): 269-278. doi: https://doi.org/10.1007/pl00011776
Gómez-Chiarri M, Kirby VL, Powers DA. Isolation and Characterization of an Actin Promoter from the Red Abalone (Haliotis rufescens). Mar Biotechnol (NY). 1999 May;1(3):269-278. doi: 10.1007/pl00011776. PMID: 10384001.
Copy Download .nbib Format: NLM
Taking sides: a response to Goodwin and Goodwin.

Nursing research

Powers BA.
PMID: 3644258
Nurs Res. 1987 Mar-Apr;36(2):122-6.

No abstract available.

Cite
Powers BA. Taking sides: a response to Goodwin and Goodwin. Nurs Res. 1987;36(2):122-6
Powers, B. A. (1987). Taking sides: a response to Goodwin and Goodwin. Nursing research, 36(2), 122-6.
Powers, B A. "Taking sides: a response to Goodwin and Goodwin." Nursing research vol. 36,2 (1987): 122-6.
Powers BA. Taking sides: a response to Goodwin and Goodwin. Nurs Res. 1987 Mar-Apr;36(2):122-6. PMID: 3644258.
Copy Download .nbib Format: NLM
Convergent automated parallel synthesis.

Drug discovery today

Powers DG, Coffen DL.
PMID: 10431148
Drug Discov Today. 1999 Aug;4(8):377-383. doi: 10.1016/s1359-6446(99)01364-1.

As combinatorial chemistry approaches its second decade of widespread use, the developmental pathways that could shape its future are becoming increasingly apparent. Progress down one of these pathways is driven by the desire to make and test more complex...

Cite
Powers DG, Coffen DL. Convergent automated parallel synthesis. Drug Discov Today. 1999;4(8):377-383doi: 10.1016/s1359-6446(99)01364-1.
Powers, D. G., & Coffen, D. L. (1999). Convergent automated parallel synthesis. Drug discovery today, 4(8), 377-383. https://doi.org/10.1016/s1359-6446(99)01364-1
Powers, and Coffen. "Convergent automated parallel synthesis." Drug discovery today vol. 4,8 (1999): 377-383. doi: https://doi.org/10.1016/s1359-6446(99)01364-1
Powers DG, Coffen DL. Convergent automated parallel synthesis. Drug Discov Today. 1999 Aug;4(8):377-383. doi: 10.1016/s1359-6446(99)01364-1. PMID: 10431148.
Copy Download .nbib Format: NLM
Intramedullary Spinal Cord Tumors.

Current treatment options in neurology

Bowers DC, Weprin BE.
PMID: 12670409
Curr Treat Options Neurol. 2003 May;5(3):207-212. doi: 10.1007/s11940-003-0011-2.

The three most common types of intramedullary spinal cord tumors are low-grade astrocytomas, ependymomas, and high-grade astrocytomas. Surgical extirpation is the necessary and sufficient primary treatment for most intramedullary spinal cord tumors. Radiation therapy may also have a role...

Cite
Bowers DC, Weprin BE. Intramedullary Spinal Cord Tumors. Curr Treat Options Neurol. 2003;5(3):207-212doi: 10.1007/s11940-003-0011-2.
Bowers, D. C., & Weprin, B. E. (2003). Intramedullary Spinal Cord Tumors. Current treatment options in neurology, 5(3), 207-212. https://doi.org/10.1007/s11940-003-0011-2
Bowers, Daniel C., and Weprin, Bradley E.. "Intramedullary Spinal Cord Tumors." Current treatment options in neurology vol. 5,3 (2003): 207-212. doi: https://doi.org/10.1007/s11940-003-0011-2
Bowers DC, Weprin BE. Intramedullary Spinal Cord Tumors. Curr Treat Options Neurol. 2003 May;5(3):207-212. doi: 10.1007/s11940-003-0011-2. PMID: 12670409.
Copy Download .nbib Format: NLM
Benign tumors of the esophagus.

The American surgeon

PUESTOW CB, GILLESBY WJ, POWERS JA.
PMID: 14362004
Am Surg. 1955 May;21(5):425-33.

No abstract available.

Cite
PUESTOW CB, GILLESBY WJ, POWERS JA. Benign tumors of the esophagus. Am Surg. 1955;21(5):425-33
PUESTOW, C. B., GILLESBY, W. J., & POWERS, J. A. (1955). Benign tumors of the esophagus. The American surgeon, 21(5), 425-33.
PUESTOW, C B, et al. "Benign tumors of the esophagus." The American surgeon vol. 21,5 (1955): 425-33.
PUESTOW CB, GILLESBY WJ, POWERS JA. Benign tumors of the esophagus. Am Surg. 1955 May;21(5):425-33. PMID: 14362004.
Copy Download .nbib Format: NLM
Thermal reactions of 8-methylbicyclo[4.2.0]oct-2-enes: competitive diradical-mediated [1,3] sigmatropic, stereomutation, and fragmentation processes.

The Journal of organic chemistry

Bogle XS, Leber PA, McCullough LA, Powers DC.
PMID: 16238327
J Org Chem. 2005 Oct 28;70(22):8913-8. doi: 10.1021/jo051505g.

[reaction: see text] At 275 degrees C, 8-exo-methylbicyclo[4.2.0]oct-2-ene (1a) undergoes a [1,3] sigmatropic rearrangement to 5-methylbicyclo[2.2.2]oct-2-enes, of which the orbital symmetry-allowed si product is only marginally favored over the forbidden sr product; that is, si/sr is 2.4. Accompanying the...

Cite
Bogle XS, Leber PA, McCullough LA, et al. Thermal reactions of 8-methylbicyclo[4.2.0]oct-2-enes: competitive diradical-mediated [1,3] sigmatropic, stereomutation, and fragmentation processes. J Org Chem. 2005;70(22):8913-8doi: 10.1021/jo051505g.
Bogle, X. S., Leber, P. A., McCullough, L. A., & Powers, D. C. (2005). Thermal reactions of 8-methylbicyclo[4.2.0]oct-2-enes: competitive diradical-mediated [1,3] sigmatropic, stereomutation, and fragmentation processes. The Journal of organic chemistry, 70(22), 8913-8. https://doi.org/10.1021/jo051505g
Bogle, Xavier S, et al. "Thermal reactions of 8-methylbicyclo[4.2.0]oct-2-enes: competitive diradical-mediated [1,3] sigmatropic, stereomutation, and fragmentation processes." The Journal of organic chemistry vol. 70,22 (2005): 8913-8. doi: https://doi.org/10.1021/jo051505g
Bogle XS, Leber PA, McCullough LA, Powers DC. Thermal reactions of 8-methylbicyclo[4.2.0]oct-2-enes: competitive diradical-mediated [1,3] sigmatropic, stereomutation, and fragmentation processes. J Org Chem. 2005 Oct 28;70(22):8913-8. doi: 10.1021/jo051505g. PMID: 16238327.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 354 entries